Ospemifene improves vaginal microbiome in postmenopausal women with vulvovaginal atrophy
Italy: An original study entitled "Effect of ospemifene on the vaginal microbiome in postmenopausal women with vulvovaginal atrophy" has stated that "Ospemifene" is beneficial for postmenopausal women in maintaining vaginal health by reducing the number of "potentially harmful" bacteria.
The study findings are published in Menopause, The Journal of the North American Menopause Society.
Researchers compared the vaginal microbiome profile of women with vulvovaginal atrophy to healthy postmenopausal women.
The team also assessed, “What are the effectiveness of Ospemifene and systemic hormone treatment on vaginal microbiome composition?”
The study summary includes the following:
- The researchers enrolled 67 postmenopausal women attending the Gynecology Clinic of Azienda Ospedaliero-Universitaria of Bologna (Italy).
- Thirty-nine women were diagnosed with atrophy, and 28 were healthy.
- In the atrophic women group, 20 received ospemifene and 19 hormone treatment.
- 16S rRNA gene sequencing was used to analyse the vaginal microbiome.
- After three months of treatment, Clinical/microbiological analyses were repeated.
- Among atrophic women, there was a significantly reduced number of lactobacillus and increased Streptococcus and Sneathia.
- A positive correlation was recorded between vaginal health index/vaginal maturation index and Lactobacillus abundance.
- Both treatment approaches effectively improved vaginal indices.
- In the women on Systemic hormone treatment, there were changes induced in the minority bacterial groups.
- Among women on ospemifene, specific bacterial taxa, like Staphylococcus and Clostridium, were eliminated.
- Bifidobacteria increased with both treatments.
To conclude, there is a significant difference between the vaginal microbiome of atrophic women and healthy postmenopausal women. Ospemifene reduces harmful bacteria and promotes good vaginal health.
Further reading:
Alvisi, Stefania MD1,2; Ceccarani, Camilla PhD3; Foschi, Claudio MD4,5; Baldassarre, Maurizio PhD2,6; Lami, Alessandra MD1,2; Severgnini, Marco MSc3; Camboni, Tania PhD3; Consolandi, Clarissa PhD3; Seracchioli, Renato MD1,2; Meriggiola, Maria Cristina MD, PhD1,2. Effect of ospemifene on the vaginal microbiome in postmenopausal women with vulvovaginal atrophy. Menopause ():10.1097/GME.0000000000002150, January 24, 2023. | DOI: 10.1097/GME.0000000000002150
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.